SecBot SecBot
8-K ·Filed Nov 4, 2026

BIO

BIO-RAD LABORATORIES, INC.
NEUTRAL
Impact 5/10
Horizondays Processed12d 11h ago SEC0000012208-26-000057
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The EPS beat and margin expansion are positive, but the full-year guidance was unchanged from the prior quarter, suggesting no acceleration in the second half. Watch for the Q4 2026 report to see if currency-neutral revenue growth can sustain or improve from the 0.7% level.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$369.00
T+0 close · Nov 4, 2026 · via day close
Latest settled
+0.40%
T+5 · $370.48 · next T+20 in 17d
Vs SPY
−2.89%
α at T+5
Latest observation
−1.22%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $369.00entry
  2. T+1 · 11d ago +3.41%α +3.09% · $381.57
  3. T+5 · 5d ago +0.40%α −2.89% · $370.48
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bio-Rad reported Q3 2026 non-GAAP EPS of $2.65, beating the $2.23 consensus by 18.8%, and revenue of $656.4M, slightly above the $650.0M estimate. Non-GAAP operating margin expanded 100bps YoY to 12.8%, and the company maintained its full-year 2026 guidance for currency-neutral revenue decline of 3.0% to growth of 0.5% and non-GAAP operating margin of 10.0-12.0%. GAAP results included a $49.8M impairment charge and $77.2M in restructuring costs, driving a GAAP operating loss.

Key Financial Metrics

EPS (Adj.)
$2.65
est $2.23 · +18.8% · GAAP: $17.02
Revenue
$656.4M
est $650.0M · +1.0% · +0.5% YoY
Rating
beat
Guidance
decline of 3.0% to growth of 0.5% (currency-neutral)
maintained
Free Cash Flow
$65.2M
Gross Margin
50.1%

Key Facts

  • Q3 2026 non-GAAP EPS $2.65 vs consensus $2.23 (beat by 18.8%)
  • Q3 2026 revenue $656.4M vs consensus $650.0M (beat by 1.0%)
  • Reported revenue +0.5% YoY; currency-neutral revenue +0.7% YoY
  • Non-GAAP gross margin 54.5% (+100bps YoY); non-GAAP operating margin 12.8% (+100bps YoY)
  • GAAP operating loss of $49.7M due to $77.2M restructuring costs and $49.8M impairment of purchased intangibles
  • Full-year 2026 guidance maintained: currency-neutral revenue decline of 3.0% to growth of 0.5%; non-GAAP operating margin 10.0-12.0%
  • Clinical Diagnostics segment revenue +2.8% currency-neutral; Life Science segment revenue -2.4% currency-neutral
  • Free cash flow $65.2M in Q3 2026 vs $89.2M in Q3 2025
  • Net cash from operations $96.4M in Q3 2026 vs $120.9M in Q3 2025

Financial Impact

Non-GAAP EPS beat consensus by $0.42 (18.8%); revenue beat by $6.4M (1.0%); non-GAAP operating margin expanded 100bps YoY

revenueepsoperating marginfree cash flow

Segment Breakdown

SegmentRevenueGrowth
Life Science$254.6M-2.8%
Clinical Diagnostics$401.8M+2.7%

Risk Factors

  • Life Science segment continues to decline (-2.4% currency-neutral) due to weak academic research market and lower process chromatography sales
  • GAAP results show significant restructuring ($77.2M) and impairment ($49.8M) charges
  • Free cash flow declined 27% YoY to $65.2M
  • Full-year guidance unchanged and still includes potential revenue decline of up to 3.0%

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
50% bullish (10 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000012208-26-000057
Document: bio-20261104.htm0000012208-26-000057
Document: a3q26earningspresentatio.htm0000012208-26-000057
Document: 0000012208-26-000057-index-headers.html0000012208-26-000057
Document: 0000012208-26-000057-index.html0000012208-26-000057
Document: 0000012208-26-000057.txt0000012208-26-000057
8-K Data (Synthetic)0000012208-26-000057

Track record

9 reports on BIO

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $370.48 Now $360.26 −2.76% settles Nov 19
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $386.00 Now $360.26 −6.67% settles Nov 18
  3. Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $386.48 Now $360.26 −6.78% settles Nov 17
  5. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 Entry $388.31 to $360.26 Now $360.26 +7.22% ▲ +7.22% +5.53% vs SPY
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $369.00 to $370.48 Now $360.26 −2.37% ▲ +0.40% −2.89% vs SPY
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $385.12 to $379.99 Now $360.26 −6.46% ▼ −1.33% −0.62% vs SPY
  8. Sep 10, 20269w ago Court Ruling Bearish 5/10 Entry $369.32 to $376.41 Now $360.26 +2.45% ▼ −1.92% −2.26% vs SPY
  9. Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $285.94 to $282.44 Now $360.26 +25.99% ▼ −1.22% −1.90% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026